According to CEO, Armon Sharei, “We have shown we can engineer virtually any cell—including T, B, NK ... with transcription factors cargo to redirect cell fate. The company recently presented ...

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic ...

This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy ...

Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...